Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West.
Since our founding in 2015, under the leadership of our experienced management team with in-depth knowledge and expertise of the evolving cancer treatment landscape, we have built a pipeline of ten (10) drug candidates across 12 programs that focus on oncology, of which five (5) drug candidates are at clinical stage. The drug candidates in our existing pipeline can be categorized into three (3) groups based on their mechanisms of action, each of which contains drug candidates at different stages of development. The first group is “tumor inhibitors”, which consists of four (4) small molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells, one of which is our Core Product, a c-Met inhibitor. The second group is “anti-cancer enhancers”, which could enhance the anti-cancer effects of other treatments. This group comprises two (2) antagonists against a cell adhesion receptor, which are being developed as adjuncts to chemotherapy. The last group is “immuno-oncology drugs”, which take the advantage of the body’s immune system to fight cancer. This group comprises four (4) drug candidates, including mono-specific and bi-specific antibodies that releases the natural brakes of immune response against cancer cells, as well as a novel cancer vaccine.
Having three (3) groups of drug candidates with different mechanisms of action would enable us to develop potential synergistic combination therapies that address unmet needs in cancer treatment.
To learn more about Apollomics, visit our website at https://www.apollomicsinc.com/
